Hal Barron, GSK R&D chief (GSK via investor day livestream)
What made GlaxoSmithKline’s Hal Barron spend $2.2B to get back into neuro? Alector flashes the data
What made GSK’s Hal Barron spend $700 million cash to get in on a pair of antibodies for neurodegeneration?
Alector flashed part of the answer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
